
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Mach7 Technologies Limited is a health information services business based in Australia. Mach7 Technologies shares (M7T) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Mach7 Technologies has a trailing 12-month revenue of around $16.9 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.37 - $1.59 |
---|---|
50-day moving average | $1.3968 |
200-day moving average | $1.1695 |
Target price | N/A |
PE ratio | 1499.9999 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.001 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$1.22
5 years (2016-04-10) | inf% |
---|
Valuing Mach7 Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mach7 Technologies 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mach7 Technologies 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1500x. In other words, Mach7 Technologies shares trade at around 1500x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Mach7 Technologies 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 million (£630,996).
The EBITDA is a measure of a Mach7 Technologies 's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $16.9 million |
---|---|
Gross profit TTM | $6.3 million |
Return on assets TTM | -9.28% |
Return on equity TTM | -17.66% |
Profit margin | -45.47% |
Book value | 0.24 |
Market capitalisation | $339.3 million |
TTM: trailing 12 months
We're not expecting Mach7 Technologies to pay a dividend over the next 12 months.
Mach7 Technologies 's shares were split on a 1:10 basis on 10 January 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mach7 Technologies shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Mach7 Technologies shares which in turn could have impacted Mach7 Technologies 's share price.
Over the last 12 months, Mach7 Technologies 's shares have ranged in value from as little as $0.37 up to $1.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Mach7 Technologies 's is 1.3909. This would suggest that Mach7 Technologies 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability solutions for healthcare enterprises worldwide. The company operates through two segments, Sale of Software Licenses and Provision of Professional Services. It offers Management Studio that enables healthcare delivery organizations to own, archive, and communicate imaging data across the enterprise and connect that data with the electronic medical record. The company's Management Studio comprises enterprise imaging platform, vendor neutral archive, communication workflow engine, routing engine, fetching engine, and migration engine products. It also provides Diagnostic Studio that includes a suite of solutions to drive specialty workflows. The company's Diagnostic Studio solutions include PACS and QC solution; and Universal Worklist. In addition, the company offers Clinical Studio, which provides access to view, navigate, review, and share patient medical data over the Web and across the enterprise. Its Clinical Studio solutions consist of clinical portal, clinical viewer, image sharing, and procedure import/export products, as well as iModality, a mobile medical image capture using smart device technology. Further, the company provides professional services, such as implementation and training, data migration, support, and maintenance services; and archive migration services. Mach7 Technologies Limited was founded in 2007 and is based in South Burlington, Vermont.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.
Steps to owning and managing Top Shelf International shares.
Steps to owning and managing K12 Inc shares from Australia.
Steps to owning and managing 2U Inc shares from Australia.
Steps to owning and managing Chegg Inc shares from Australia.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.